2025 Q4 -tulosraportti
Vain PDF
16 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·23 min sittenHi everyone. Can someone tell me in plain English what I should do if I buy a warrant and what the advantages and disadvantages are. 🤪🙏🙏🙏
·3 t sittenEVERYONE TALKS ABOUT THE ENGINE. ALMOST NO ONE UNDERSTANDS HOW IT WILL WIN THE RACE. 🧬🏎️ People have understood that circVec is a fantastic expression engine. That's good. But a Formula 1 engine is useless if you don't have a chassis to put it in. You have to get the technology completely into the right cells, in the right tissue, without destroying the body along the way. Delivery is the holy grail in gene therapy. This is where 90 % of companies fail. And this is exactly where Circio is now building a masterpiece of an ecosystem. They are not locking themselves into one route. They are building three. 1. The AAV track (Classic gene therapy – Heart, Eye, CNS) 👁️🫀🧠 This is the most mature track, and the data we have seen leading up to ASGCT is brutal: • Eye: Over 60x higher expression. 22x higher expression at 1/10 of the dose. • Heart: 40x higher expression. • The key: They get massively more RNA output without increasing the amount of AAV (viral vector). What it means: Lower dose, less toxicity (poisonousness) and an enormously improved safety margin. They make the established standard (AAV) exponentially better. 2. The LNP track (Acuitas – In vivo CAR-T) 🩸🎯 Forget classic gene therapy for a second. These are targeted lipid nanoparticles directly against T-cells for cancer and autoimmune diseases. The problem with regular mRNA in LNP is that the effect is often too short-lived. The solution? circVec. If Circio and Acuitas prove that circular RNA provides a longer, more stable effect inside a T-cell, we are talking about a paradigm shift in cell therapy. This is billion-dollar territory. 3. The Peptide track (TraffikGene – Non-viral) 🧬🚀 This might sound "nerdy", but strategically it's brilliant. This is a third, completely independent route based on peptide carriers to reach new tissues and cell types. Why are they doing this? To prove one massive point: circVec is delivery-agnostic. Let that sink in. Circio is not a company praying to higher powers that their one medicine hits. They are building an engine that can be plugged into AAV. Into LNP. Into peptides. They are building "Intel Inside" for next-generation gene and cell therapy. If AAV hits, the case is enormous. If LNP/Acuitas hits, the case is astronomical. If the technology works across all... then Circio is no longer a regular biotech company. Then they are critical infrastructure for the entire industry. People sell because the stock price stands still for a day. I am looking at a company that systematically builds roads into the entire delivery ecosystem. Brick by brick. We know what we own. ♟️🧱🍷·31 min sitten · MuokattuPrice 9.4, time to close the gap upwards towards 250?- 300? 400 ? kroner..l Time to wake up, folks. This is happening with a methodology that suggests they know what they have in store.
·6 t sittenWhy is the stock exchange still closed?
·4 t sittenStock Exchange Holidays 2026 (Norway) * January 1 – Closed * April 2–6 (Easter) – Closed (several days) * May 1 – Closed * May 14 (Ascension Day) – Closed * May 25 (Whit Monday) – Closed * December 24 – Closed * December 25 – Closed * December 26 – Closed * December 31 – Closed
·10 t sitten
·8 t sittenCorrect with 15000 owners
·6 t sittenHaha, I am on paternity leave and am deeply affected by sleep deprivation. You are right, yes:)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
16 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 min sittenHi everyone. Can someone tell me in plain English what I should do if I buy a warrant and what the advantages and disadvantages are. 🤪🙏🙏🙏
- ·3 t sittenEVERYONE TALKS ABOUT THE ENGINE. ALMOST NO ONE UNDERSTANDS HOW IT WILL WIN THE RACE. 🧬🏎️ People have understood that circVec is a fantastic expression engine. That's good. But a Formula 1 engine is useless if you don't have a chassis to put it in. You have to get the technology completely into the right cells, in the right tissue, without destroying the body along the way. Delivery is the holy grail in gene therapy. This is where 90 % of companies fail. And this is exactly where Circio is now building a masterpiece of an ecosystem. They are not locking themselves into one route. They are building three. 1. The AAV track (Classic gene therapy – Heart, Eye, CNS) 👁️🫀🧠 This is the most mature track, and the data we have seen leading up to ASGCT is brutal: • Eye: Over 60x higher expression. 22x higher expression at 1/10 of the dose. • Heart: 40x higher expression. • The key: They get massively more RNA output without increasing the amount of AAV (viral vector). What it means: Lower dose, less toxicity (poisonousness) and an enormously improved safety margin. They make the established standard (AAV) exponentially better. 2. The LNP track (Acuitas – In vivo CAR-T) 🩸🎯 Forget classic gene therapy for a second. These are targeted lipid nanoparticles directly against T-cells for cancer and autoimmune diseases. The problem with regular mRNA in LNP is that the effect is often too short-lived. The solution? circVec. If Circio and Acuitas prove that circular RNA provides a longer, more stable effect inside a T-cell, we are talking about a paradigm shift in cell therapy. This is billion-dollar territory. 3. The Peptide track (TraffikGene – Non-viral) 🧬🚀 This might sound "nerdy", but strategically it's brilliant. This is a third, completely independent route based on peptide carriers to reach new tissues and cell types. Why are they doing this? To prove one massive point: circVec is delivery-agnostic. Let that sink in. Circio is not a company praying to higher powers that their one medicine hits. They are building an engine that can be plugged into AAV. Into LNP. Into peptides. They are building "Intel Inside" for next-generation gene and cell therapy. If AAV hits, the case is enormous. If LNP/Acuitas hits, the case is astronomical. If the technology works across all... then Circio is no longer a regular biotech company. Then they are critical infrastructure for the entire industry. People sell because the stock price stands still for a day. I am looking at a company that systematically builds roads into the entire delivery ecosystem. Brick by brick. We know what we own. ♟️🧱🍷·31 min sitten · MuokattuPrice 9.4, time to close the gap upwards towards 250?- 300? 400 ? kroner..l Time to wake up, folks. This is happening with a methodology that suggests they know what they have in store.
- ·6 t sittenWhy is the stock exchange still closed?·4 t sittenStock Exchange Holidays 2026 (Norway) * January 1 – Closed * April 2–6 (Easter) – Closed (several days) * May 1 – Closed * May 14 (Ascension Day) – Closed * May 25 (Whit Monday) – Closed * December 24 – Closed * December 25 – Closed * December 26 – Closed * December 31 – Closed
- ·10 t sitten·8 t sittenCorrect with 15000 owners·6 t sittenHaha, I am on paternity leave and am deeply affected by sleep deprivation. You are right, yes:)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
16 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·23 min sittenHi everyone. Can someone tell me in plain English what I should do if I buy a warrant and what the advantages and disadvantages are. 🤪🙏🙏🙏
- ·3 t sittenEVERYONE TALKS ABOUT THE ENGINE. ALMOST NO ONE UNDERSTANDS HOW IT WILL WIN THE RACE. 🧬🏎️ People have understood that circVec is a fantastic expression engine. That's good. But a Formula 1 engine is useless if you don't have a chassis to put it in. You have to get the technology completely into the right cells, in the right tissue, without destroying the body along the way. Delivery is the holy grail in gene therapy. This is where 90 % of companies fail. And this is exactly where Circio is now building a masterpiece of an ecosystem. They are not locking themselves into one route. They are building three. 1. The AAV track (Classic gene therapy – Heart, Eye, CNS) 👁️🫀🧠 This is the most mature track, and the data we have seen leading up to ASGCT is brutal: • Eye: Over 60x higher expression. 22x higher expression at 1/10 of the dose. • Heart: 40x higher expression. • The key: They get massively more RNA output without increasing the amount of AAV (viral vector). What it means: Lower dose, less toxicity (poisonousness) and an enormously improved safety margin. They make the established standard (AAV) exponentially better. 2. The LNP track (Acuitas – In vivo CAR-T) 🩸🎯 Forget classic gene therapy for a second. These are targeted lipid nanoparticles directly against T-cells for cancer and autoimmune diseases. The problem with regular mRNA in LNP is that the effect is often too short-lived. The solution? circVec. If Circio and Acuitas prove that circular RNA provides a longer, more stable effect inside a T-cell, we are talking about a paradigm shift in cell therapy. This is billion-dollar territory. 3. The Peptide track (TraffikGene – Non-viral) 🧬🚀 This might sound "nerdy", but strategically it's brilliant. This is a third, completely independent route based on peptide carriers to reach new tissues and cell types. Why are they doing this? To prove one massive point: circVec is delivery-agnostic. Let that sink in. Circio is not a company praying to higher powers that their one medicine hits. They are building an engine that can be plugged into AAV. Into LNP. Into peptides. They are building "Intel Inside" for next-generation gene and cell therapy. If AAV hits, the case is enormous. If LNP/Acuitas hits, the case is astronomical. If the technology works across all... then Circio is no longer a regular biotech company. Then they are critical infrastructure for the entire industry. People sell because the stock price stands still for a day. I am looking at a company that systematically builds roads into the entire delivery ecosystem. Brick by brick. We know what we own. ♟️🧱🍷·31 min sitten · MuokattuPrice 9.4, time to close the gap upwards towards 250?- 300? 400 ? kroner..l Time to wake up, folks. This is happening with a methodology that suggests they know what they have in store.
- ·6 t sittenWhy is the stock exchange still closed?·4 t sittenStock Exchange Holidays 2026 (Norway) * January 1 – Closed * April 2–6 (Easter) – Closed (several days) * May 1 – Closed * May 14 (Ascension Day) – Closed * May 25 (Whit Monday) – Closed * December 24 – Closed * December 25 – Closed * December 26 – Closed * December 31 – Closed
- ·10 t sitten·8 t sittenCorrect with 15000 owners·6 t sittenHaha, I am on paternity leave and am deeply affected by sleep deprivation. You are right, yes:)
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt